Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Lung Cancer

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 96 articles:
HTML format
Text format



Single Articles


    April 2019
  1. BEZJAK A, Paulus R, Gaspar LE, Timmerman RD, et al
    Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial.
    J Clin Oncol. 2019 Apr 3:JCO1800622. doi: 10.1200/JCO.18.00622.
    PubMed     Text format     Abstract available


    March 2019
  2. SHAW AT, Solomon BJ, Besse B, Bauer TM, et al
    ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2019 Mar 20:JCO1802236. doi: 10.1200/JCO.18.02236.
    PubMed     Text format     Abstract available


    February 2019
  3. CAMIDGE DR, Davies KD
    MET Copy Number as a Secondary Driver of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in EGFR-Mutant Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2019 Feb 27:JCO1900033. doi: 10.1200/JCO.19.00033.
    PubMed     Text format    


  4. READY N, Hellmann MD, Awad MM, Otterson GA, et al
    First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.
    J Clin Oncol. 2019 Feb 20:JCO1801042. doi: 10.1200/JCO.18.01042.
    PubMed     Text format     Abstract available


    January 2019
  5. LAI GGY, Lim TH, Lim J, Liew PJR, et al
    Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2019 Jan 24:JCO1800177. doi: 10.1200/JCO.18.00177.
    PubMed     Text format     Abstract available


  6. LISBERG A, Garon EB
    Does Platinum-Based Chemotherapy Still Have a Role in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer?
    J Clin Oncol. 2019 Jan 24:JCO1801534. doi: 10.1200/JCO.18.01534.
    PubMed     Text format    


  7. RECK M, Rodriguez-Abreu D, Robinson AG, Hui R, et al
    Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.
    J Clin Oncol. 2019 Jan 8:JCO1800149. doi: 10.1200/JCO.18.00149.
    PubMed     Text format     Abstract available


    December 2018
  8. MARCOUX N, Gettinger SN, O'Kane G, Arbour KC, et al
    EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.
    J Clin Oncol. 2018 Dec 14:JCO1801585. doi: 10.1200/JCO.18.01585.
    PubMed     Text format     Abstract available


  9. OWONIKOKO TK, Dahlberg SE, Sica GL, Wagner LI, et al
    Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study.
    J Clin Oncol. 2018 Dec 5:JCO1800264. doi: 10.1200/JCO.18.00264.
    PubMed     Text format     Abstract available


    November 2018
  10. LIANG F
    Is SLFN11 a Promising Predictive Biomarker of Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Small-Cell Lung Cancer? Not Yet!
    J Clin Oncol. 2018 Nov 29:JCO1800993. doi: 10.1200/JCO.18.00993.
    PubMed     Text format    


  11. PENNELL NA, Neal JW, Chaft JE, Azzoli CG, et al
    SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2018 Nov 16:JCO1800131. doi: 10.1200/JCO.18.00131.
    PubMed     Text format     Abstract available


    October 2018
  12. ZENG H, Yuan S, Yu J
    Prophylactic Cranial Irradiation in Non-Small-Cell Lung Cancer: Hope or Hype?
    J Clin Oncol. 2018 Oct 22:JCO1800617. doi: 10.1200/JCO.18.00617.
    PubMed     Text format    


  13. ADDEO A, Caparrotti F, Picardi C, Dietrich PY, et al
    Prophylactic Cranial Irradiation in Stage III Non-Small-Cell Lung Cancer: Overall Survival Should Not Necessarily Be the Final End Point.
    J Clin Oncol. 2018 Oct 22:JCO1800461. doi: 10.1200/JCO.18.00461.
    PubMed     Text format    


  14. RUSTHOVEN CG
    Prophylactic Cranial Irradiation in Non-Small-Cell Lung Cancer: The Costs Outweigh the Benefits.
    J Clin Oncol. 2018 Oct 22:JCO1800732. doi: 10.1200/JCO.18.00732.
    PubMed     Text format    


    September 2018
  15. ZENG L, Yang N, Zhang Y
    Should Crizotinib Take It All in ROS1-Positive Non-Small-Cell Lung Cancer?
    J Clin Oncol. 2018 Sep 13:JCO1800119. doi: 10.1200/JCO.18.00119.
    PubMed     Text format    


    August 2018
  16. WU YL, Zhang L, Kim DW, Liu X, et al
    Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Endothelial Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2018 Aug 29:JCO2018777326. doi: 10.1200/JCO.2018.77.7326.
    PubMed     Text format     Abstract available


  17. REUNGWETWATTANA T, Nakagawa K, Cho BC, Cobo M, et al
    CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2018 Aug 28:JCO2018783118. doi: 10.1200/JCO.2018.78.3118.
    PubMed     Text format     Abstract available


  18. WANG YN, Yao S, Wang CL, Li MS, et al
    Clinical Significance of 4L Lymph Node Dissection in Left Lung Cancer.
    J Clin Oncol. 2018 Aug 27:JCO2018787101. doi: 10.1200/JCO.2018.78.7101.
    PubMed     Text format     Abstract available


  19. DE RUYSSCHER DKM, Decaluwe H
    4L Lymph Node Involvement in Left-Sided Lung Cancer: Unique or Not?
    J Clin Oncol. 2018 Aug 27:JCO2018793299. doi: 10.1200/JCO.2018.79.3299.
    PubMed     Text format    


  20. ARBOUR KC, Mezquita L, Long N, Rizvi H, et al
    Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2018 Aug 20:JCO2018790006. doi: 10.1200/JCO.2018.79.0006.
    PubMed     Text format     Abstract available


  21. DEVARAKONDA S, Rotolo F, Tsao MS, Lanc I, et al
    Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2018 Aug 14:JCO2018781963. doi: 10.1200/JCO.2018.78.1963.
    PubMed     Text format     Abstract available


    July 2018
  22. WU YL, Ahn MJ, Garassino MC, Han JY, et al
    CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).
    J Clin Oncol. 2018 Jul 30:JCO2018779363. doi: 10.1200/JCO.2018.77.9363.
    PubMed     Text format     Abstract available


  23. GRIDELLI C, Morabito A, Cavanna L, Luciani A, et al
    Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials.
    J Clin Oncol. 2018 Jul 20:JCO2017768390. doi: 10.1200/JCO.2017.76.8390.
    PubMed     Text format     Abstract available


    June 2018
  24. DONINGTON JS
    Thoracotomy for Stage I Lung Cancer Resections: A Procedure Past Its Time.
    J Clin Oncol. 2018 Jun 26:JCO2018793042. doi: 10.1200/JCO.2018.79.3042.
    PubMed     Text format    


  25. ZWEIG JR, Neal JW
    Infiltrating the Blood-Brain Barrier in ALK-Positive Lung Cancer.
    J Clin Oncol. 2018 Jun 25:JCO2018788554. doi: 10.1200/JCO.2018.78.8554.
    PubMed     Text format    


  26. PIETANZA MC, Waqar SN, Krug LM, Dowlati A, et al
    Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.
    J Clin Oncol. 2018 Jun 15:JCO2018777672. doi: 10.1200/JCO.2018.77.7672.
    PubMed     Text format     Abstract available


  27. MOK TS, Cheng Y, Zhou X, Lee KH, et al
    Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
    J Clin Oncol. 2018 Jun 4:JCO2018787994. doi: 10.1200/JCO.2018.78.7994.
    PubMed     Text format     Abstract available


  28. PIOTROWSKA Z, Gainor JF
    ARCHER 1050: Hitting an Important Mark in EGFR-Mutant Lung Cancer?
    J Clin Oncol. 2018 Jun 4:JCO2018793059. doi: 10.1200/JCO.2018.79.3059.
    PubMed     Text format    


    May 2018
  29. BOFFA DJ, Kosinski AS, Furnary AP, Kim S, et al
    Minimally Invasive Lung Cancer Surgery Performed by Thoracic Surgeons as Effective as Thoracotomy.
    J Clin Oncol. 2018 May 23:JCO2018778977. doi: 10.1200/JCO.2018.77.8977.
    PubMed     Text format     Abstract available


  30. DE RUYSSCHER D, Dingemans AC, Praag J, Belderbos J, et al
    Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 Study.
    J Clin Oncol. 2018 May 22:JCO2017775817. doi: 10.1200/JCO.2017.77.5817.
    PubMed     Text format     Abstract available


  31. CAMIDGE DR, Kim DW, Tiseo M, Langer CJ, et al
    Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials.
    J Clin Oncol. 2018 May 16:JCO2017775841. doi: 10.1200/JCO.2017.77.5841.
    PubMed     Text format     Abstract available


  32. SOLOMON BJ, Kim DW, Wu YL, Nakagawa K, et al
    Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2018 May 16:JCO2017774794. doi: 10.1200/JCO.2017.77.4794.
    PubMed     Text format     Abstract available


  33. COPUR MS, Crockett D, Gauchan D, Ramaekers R, et al
    Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Targeted Therapy.
    J Clin Oncol. 2018 May 15:JCO2018788240. doi: 10.1200/JCO.2018.78.8240.
    PubMed     Text format    


  34. LEONARDI GC, Gainor JF, Altan M, Kravets S, et al
    Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders.
    J Clin Oncol. 2018 May 10:JCO2017770305. doi: 10.1200/JCO.2017.77.0305.
    PubMed     Text format     Abstract available


  35. RENGAN R, Redman M, Zeng J
    Challenge of Proving the Value of Proton Therapy in an Unselected Patient Population in the Era of Precision Oncology: The Fallacy of a One-Size-Fits-All Strategy in Radiotherapy for Lung Cancer.
    J Clin Oncol. 2018 May 10:JCO2018783803. doi: 10.1200/JCO.2018.78.3803.
    PubMed     Text format    


  36. LEE CK, Novello S, Ryden A, Mann H, et al
    Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 Trial.
    J Clin Oncol. 2018 May 7:JCO2017772293. doi: 10.1200/JCO.2017.77.2293.
    PubMed     Text format     Abstract available


    April 2018
  37. REINMUTH N, Reck M
    Breaking the Glass Ceiling of Overall Survival in Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2018 Apr 30:JCO2018782102. doi: 10.1200/JCO.2018.78.2102.
    PubMed     Text format    


    March 2018
  38. WU YL, Yang JC, Kim DW, Lu S, et al
    Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2018 Mar 29:JCO2017755587. doi: 10.1200/JCO.2017.75.5587.
    PubMed     Text format     Abstract available


  39. GETTINGER S, Horn L, Jackman D, Spigel D, et al
    Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.
    J Clin Oncol. 2018 Mar 23:JCO2017770412. doi: 10.1200/JCO.2017.77.0412.
    PubMed     Text format     Abstract available


  40. LU S, Chang J, Liu X, Shi J, et al
    Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous NonSmall-Cell Lung Cancer.
    J Clin Oncol. 2018 Mar 12:JCO2017767145. doi: 10.1200/JCO.2017.76.7145.
    PubMed     Text format     Abstract available


    February 2018
  41. KALEMKERIAN GP, Narula N, Kennedy EB, Biermann WA, et al
    Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for
    J Clin Oncol. 2018 Feb 5:JCO2017767293. doi: 10.1200/JCO.2017.76.7293.
    PubMed     Text format     Abstract available


    January 2018
  42. LIN JJ, Zhu VW, Yoda S, Yeap BY, et al
    Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.
    J Clin Oncol. 2018 Jan 26:JCO2017762294. doi: 10.1200/JCO.2017.76.2294.
    PubMed     Text format     Abstract available


  43. STOKES WA, Bronsert MR, Meguid RA, Blum MG, et al
    Post-Treatment Mortality After Surgery and Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2018 Jan 18:JCO2017756536. doi: 10.1200/JCO.2017.75.6536.
    PubMed     Text format     Abstract available


  44. RIZVI H, Sanchez-Vega F, La K, Chatila W, et al
    Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand (PD-L)-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
    J Clin Oncol. 2018 Jan 16:JCO2017753384. doi: 10.1200/JCO.2017.75.3384.
    PubMed     Text format     Abstract available


  45. LIAO Z, Lee JJ, Komaki R, Gomez DR, et al
    Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2018 Jan 2:JCO2017740720. doi: 10.1200/JCO.2017.74.0720.
    PubMed     Text format     Abstract available


    December 2017
  46. OBEID R, Pietrzik K
    Smoking, B Vitamins, and Lung Cancer: The Chicken or the Egg Causality Dilemma.
    J Clin Oncol. 2017 Dec 28:JCO2017759472. doi: 10.1200/JCO.2017.75.9472.
    PubMed     Text format    


  47. FRANCIS S, Orton A, Stoddard G, Tao R, et al
    Sequencing of Postoperative Radiotherapy and Chemotherapy for Locally Advanced or Incompletely Resected Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2017 Dec 13:JCO2017744771. doi: 10.1200/JCO.2017.74.4771.
    PubMed     Text format     Abstract available


    November 2017
  48. VAN HOEF MEHM
    Additional Recommendations for ALK Gene-Rearranged Non-Small-Cell Lung Cancer to the Recently Updated American Society of Clinical Oncology Guideline for Stage IV Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2017 Nov 22:JCO2017758367. doi: 10.1200/JCO.2017.75.8367.
    PubMed     Text format    


  49. SCHNEIDER BJ, Daly ME, Kennedy EB, Antonoff MB, et al
    Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline.
    J Clin Oncol. 2017 Nov 6:JCO2017749671. doi: 10.1200/JCO.2017.74.9671.
    PubMed     Text format     Abstract available


  50. GROSSO F, Steele N, Novello S, Nowak AK, et al
    Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.
    J Clin Oncol. 2017;35:3591-3600.
    PubMed     Text format     Abstract available


  51. WHITNEY RL, Bell JF, Tancredi DJ, Romano PS, et al
    Hospitalization Rates and Predictors of Rehospitalization Among Individuals With Advanced Cancer in the Year After Diagnosis.
    J Clin Oncol. 2017;35:3610-3617.
    PubMed     Text format     Abstract available


    October 2017
  52. BUTTNER R, Gosney JR, Skov BG, Adam J, et al
    Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2017 Oct 20:JCO2017747642. doi: 10.1200/JCO.2017.74.7642.
    PubMed     Text format     Abstract available


  53. HORN L, Spigel DR, Vokes EE, Holgado E, et al
    Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).
    J Clin Oncol. 2017 Oct 12:JCO2017743062. doi: 10.1200/JCO.2017.74.3062.
    PubMed     Text format     Abstract available


  54. SMIT EF, Haanen JBAG
    Pembrolizumab in Small-Cell Lung Cancer: In Search of the Best Biomarker.
    J Clin Oncol. 2017 Oct 10:JCO2017745141. doi: 10.1200/JCO.2017.74.5141.
    PubMed     Text format    


  55. NELSON DB, Rice DC, Niu J, Atay S, et al
    Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis.
    J Clin Oncol. 2017;35:3354-3362.
    PubMed     Text format     Abstract available


  56. MOK TSK, Kim SW, Wu YL, Nakagawa K, et al
    Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses.
    J Clin Oncol. 2017 Oct 2:JCO2017739250. doi: 10.1200/JCO.2017.73.9250.
    PubMed     Text format     Abstract available


    September 2017
  57. KUBOTA K, Yoshioka H, Oshita F, Hida T, et al
    Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2017 Sep 13:JCO2017727297. doi: 10.1200/JCO.2017.72.7297.
    PubMed     Text format     Abstract available


  58. O'NEILL AF, Towbin AJ, Krailo MD, Xia C, et al
    Characterization of Pulmonary Metastases in Children With Hepatoblastoma Treated on Children's Oncology Group Protocol AHEP0731 (The Treatment of Children With All Stages of Hepatoblastoma): A Report From the Children's Oncology Group.
    J Clin Oncol. 2017 Sep 11:JCO2017735654. doi: 10.1200/JCO.2017.73.5654.
    PubMed     Text format     Abstract available


  59. LEE JK, Lee J, Kim S, Kim S, et al
    Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas.
    J Clin Oncol. 2017;35:3065-3074.
    PubMed     Text format     Abstract available


  60. KRIS MG, Gaspar LE, Chaft JE, Kennedy EB, et al
    Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update.
    J Clin Oncol. 2017;35:2960-2974.
    PubMed     Text format     Abstract available


    August 2017
  61. GOVINDAN R, Szczesna A, Ahn MJ, Schneider CP, et al
    Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2017 Aug 30:JCO2016717629. doi: 10.1200/JCO.2016.71.7629.
    PubMed     Text format     Abstract available


  62. RAMALINGAM SS, Yang JC, Lee CK, Kurata T, et al
    Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2017 Aug 25:JCO2017747576. doi: 10.1200/JCO.2017.74.7576.
    PubMed     Text format     Abstract available


  63. BRASKY TM, White E, Chen CL
    Long-Term, Supplemental, One-Carbon Metabolism-Related Vitamin B Use in Relation to Lung Cancer Risk in the Vitamins and Lifestyle (VITAL) Cohort.
    J Clin Oncol. 2017 Aug 22:JCO2017727735. doi: 10.1200/JCO.2017.72.7735.
    PubMed     Text format     Abstract available


  64. OTT PA, Elez E, Hiret S, Kim DW, et al
    Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study.
    J Clin Oncol. 2017 Aug 16:JCO2017725069. doi: 10.1200/JCO.2017.72.5069.
    PubMed     Text format     Abstract available


  65. HANNA N, Johnson D, Temin S, Baker S Jr, et al
    Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
    J Clin Oncol. 2017 Aug 14:JCO2017746065. doi: 10.1200/JCO.2017.74.6065.
    PubMed     Text format     Abstract available


  66. IKOMA N, You YN, Bednarski BK, Rodriguez-Bigas MA, et al
    Impact of Recurrence and Salvage Surgery on Survival After Multidisciplinary Treatment of Rectal Cancer.
    J Clin Oncol. 2017;35:2631-2638.
    PubMed     Text format     Abstract available


  67. NIPP RD, Greer JA, El-Jawahri A, Moran SM, et al
    Coping and Prognostic Awareness in Patients With Advanced Cancer.
    J Clin Oncol. 2017;35:2551-2557.
    PubMed     Text format     Abstract available


    July 2017
  68. YANG JJ, Yu D, Takata Y, Smith-Warner SA, et al
    Dietary Fat Intake and Lung Cancer Risk: A Pooled Analysis.
    J Clin Oncol. 2017 Jul 25:JCO2017733329. doi: 10.1200/JCO.2017.73.3329.
    PubMed     Text format     Abstract available


  69. TAN DSW
    Changing the Natural History of Non-Small-Cell Lung Cancer Through Upfront Programmed Death Protein 1/Programmed Death-Ligand 1 Blockade.
    J Clin Oncol. 2017 Jul 17:JCO2017736215. doi: 10.1200/JCO.2017.73.6215.
    PubMed     Text format    


  70. FARAGO AF, Piotrowska Z, Sequist LV
    Unlocking the Mystery of Small-Cell Lung Cancer Transformations in EGFR Mutant Adenocarcinoma.
    J Clin Oncol. 2017 Jul 10:JCO2017735696. doi: 10.1200/JCO.2017.73.5696.
    PubMed     Text format    


  71. BENDZSAK AM, Baxter NN, Darling GE, Austin PC, et al
    Regionalization and Outcomes of Lung Cancer Surgery in Ontario, Canada.
    J Clin Oncol. 2017 Jul 6:JCO2016698076. doi: 10.1200/JCO.2016.69.8076.
    PubMed     Text format     Abstract available


    June 2017
  72. HAN SS, Rivera GA, Tammemagi MC, Plevritis SK, et al
    Risk Stratification for Second Primary Lung Cancer.
    J Clin Oncol. 2017 Jun 23:JCO2017724203. doi: 10.1200/JCO.2017.72.4203.
    PubMed     Text format     Abstract available


  73. BURRIS HA, Infante JR, Ansell SM, Nemunaitis JJ, et al
    Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.
    J Clin Oncol. 2017;35:2028-2036.
    PubMed     Text format     Abstract available


  74. PETERS S, Gettinger S, Johnson ML, Janne PA, et al
    Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).
    J Clin Oncol. 2017 Jun 13:JCO2016719476. doi: 10.1200/JCO.2016.71.9476.
    PubMed     Text format     Abstract available


  75. JALAL SI, Lavin P, Lo G, Lebel F, et al
    Carboplatin and Etoposide With or Without Palifosfamide in Untreated Extensive-Stage Small-Cell Lung Cancer: A Multicenter, Adaptive, Randomized Phase III Study (MATISSE).
    J Clin Oncol. 2017 Jun 12:JCO2016717454. doi: 10.1200/JCO.2016.71.7454.
    PubMed     Text format     Abstract available


    May 2017
  76. HEIST RS, Guarino MJ, Masters G, Purcell WT, et al
    Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.
    J Clin Oncol. 2017 May 26:JCO2016721894. doi: 10.1200/JCO.2016.72.1894.
    PubMed     Text format     Abstract available


  77. EBERHARDT WEE
    How Should We Choose the Best Therapy for Elderly Patients With Stage III Non-Small-Cell Lung Cancer?
    J Clin Oncol. 2017 May 24:JCO2017729053. doi: 10.1200/JCO.2017.72.9053.
    PubMed     Text format    


  78. LIM SM, Kim HR, Lee JS, Lee KH, et al
    Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.
    J Clin Oncol. 2017 May 18:JCO2016713701. doi: 10.1200/JCO.2016.71.3701.
    PubMed     Text format     Abstract available


  79. OU SI
    Further Advances in the Management of Anaplastic Lymphoma Kinase-Mutated Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2017 May 11:JCO2017731323. doi: 10.1200/JCO.2017.73.1323.
    PubMed     Text format    


  80. STINCHCOMBE TE, Zhang Y, Vokes EE, Schiller JH, et al
    Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies.
    J Clin Oncol. 2017 May 11:JCO2016714758. doi: 10.1200/JCO.2016.71.4758.
    PubMed     Text format     Abstract available


  81. EDELMAN MJ, Wang X, Hodgson L, Cheney RT, et al
    Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance).
    J Clin Oncol. 2017 May 10:JCO2016713743. doi: 10.1200/JCO.2016.71.3743.
    PubMed     Text format     Abstract available


  82. POPAT S
    Do Statins Improve Survival in Small-Cell Lung Cancer?
    J Clin Oncol. 2017;35:1497-1498.
    PubMed     Text format    


  83. CHALMERS A, Akerley W
    Retrospective, Multi-Institutional Analysis of Sequential Treatment of Brain Metastases in Treatment-Naive, Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer Should Not Define the Standard of Practice.
    J Clin Oncol. 2017 May 8:JCO2017727255. doi: 10.1200/JCO.2017.72.7255.
    PubMed     Text format    


  84. KIM DW, Tiseo M, Ahn MJ, Reckamp KL, et al
    Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.
    J Clin Oncol. 2017 May 5:JCO2016715904. doi: 10.1200/JCO.2016.71.5904.
    PubMed     Text format     Abstract available


  85. GAUTSCHI O, Milia J, Filleron T, Wolf J, et al
    Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.
    J Clin Oncol. 2017;35:1403-1410.
    PubMed     Text format     Abstract available


    April 2017
  86. SHEPHERD FA, Lacas B, Le Teuff G, Hainaut P, et al
    Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy.
    J Clin Oncol. 2017 Apr 28:JCO2016712893. doi: 10.1200/JCO.2016.71.2893.
    PubMed     Text format     Abstract available


  87. KAMDAR MK, Smith SM
    Extranodal Marginal Zone Lymphoma: No Longer Just a Sidekick.
    J Clin Oncol. 2017 Apr 27:JCO2017722835. doi: 10.1200/JCO.2017.72.2835.
    PubMed     Text format     Abstract available


  88. ZHONG WZ, Liu SY, Wu YL
    Numbers or Stations: From Systematic Sampling to Individualized Lymph Node Dissection in Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2017;35:1143-1145.
    PubMed     Text format    


  89. PAGLIARO LC
    Role of High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Men With Previously Treated Germ Cell Tumors.
    J Clin Oncol. 2017;35:1036-1040.
    PubMed     Text format     Abstract available


    March 2017
  90. TAYLOR C, Correa C, Duane FK, Aznar MC, et al
    Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials.
    J Clin Oncol. 2017 Mar 20:JCO2016720722. doi: 10.1200/JCO.2016.72.0722.
    PubMed     Text format     Abstract available


  91. SUD A, Thomsen H, Sundquist K, Houlston RS, et al
    Risk of Second Cancer in Hodgkin Lymphoma Survivors and Influence of Family History.
    J Clin Oncol. 2017 Mar 13:JCO2016709709. doi: 10.1200/JCO.2016.70.9709.
    PubMed     Text format     Abstract available


  92. TEMEL JS, Greer JA, El-Jawahri A, Pirl WF, et al
    Effects of Early Integrated Palliative Care in Patients With Lung and GI Cancer: A Randomized Clinical Trial.
    J Clin Oncol. 2017;35:834-841.
    PubMed     Text format     Abstract available


    February 2017
  93. SPIGEL DR, Edelman MJ, O'Byrne K, Paz-Ares L, et al
    Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.
    J Clin Oncol. 2017;35:412-420.
    PubMed     Text format     Abstract available


    December 2016
  94. NAGTEGAAL ID, Knijn N, Hugen N, Marshall HC, et al
    Tumor Deposits in Colorectal Cancer: Improving the Value of Modern Staging-A Systematic Review and Meta-Analysis.
    J Clin Oncol. 2016 Dec 28:JCO2016689091.
    PubMed     Text format     Abstract available


  95. WARDAK Z, Choy H
    Improving Treatment Options for Brain Metastases From ALK-Positive Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016;34:4064-4065.
    PubMed     Text format    


    March 2016
  96. HALABI S, Kelly WK, Ma H, Zhou H, et al
    Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2016 Mar 7. pii: JCO657270.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: